Effects of various flavonoids on the -synuclein fibrillation process

Parkinson's Disease

Volumn , Issue , 2010, Pages

  Uversky, Vladimir N ^a,b,c   Meng, Xiaoyun ^a   Munishkina, Larissa A ^a   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTHRAQUINONE DERIVATIVE; APIGENIN; CATECHIN; CHRYSOERIOL; DIOSMETIN; EMODIN; ERIODICTYOL; FLAVANONE; FLAVONOID; FLAVONOL; GENISTEIN; HESPERETIN; HOMOERIODICTYOL; ISOFLAVONE; ISORHAMNETIN; LUTEOLIN; MYRICETIN; QUERCETIN; TAMARIXETIN; UNCLASSIFIED DRUG; WOGONIN;

ALZHEIMER DISEASE; ARTICLE; BACTERIAL CELL; CHINESE MEDICINE; COMPETITIVE INHIBITION; DRUG SCREENING; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ESCHERICHIA COLI; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

EID: 77955946838     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.4061/2010/650794     Document Type: Article

References (79)

1. de Rijk M. C., Tzourio C., Breteler M. M., Prevalence of parkinsonism and Parkinsons disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinsons disease Journal of Neurology, Neurosurgery Psychiatry 1997 62 1 10 15
2. Dunnett S. B., Bjorklund A., Prospects for new restorative and neuroprotective treatments in Parkinsons disease Nature 1999 399 A32 A39
3. Forno L. S., Neuropathology of Parkinsons disease Journal of Neuropathology and Experimental Neurology 1996 55 3 259 272
4. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., Goedert M., -synuclein in Lewy bodies Nature 1997 388 6645 839 840
5. Eriksen J. L., Wszolek Z., Petrucelli L., Molecular pathogenesis of Parkinson disease Archives of Neurology 2005 62 3 353 357
6. Eriksen J. L., Dawson T. M., Dickson D. W., Petrucelli L., Caught in the act: -synuclein is the culprit in Parkinsons disease Neuron 2003 40 3 453 456
7. Selkoe D. J., Translating cell biology into therapeutic advances in Alzheimers disease Nature 1999 399 A23 A31
8. Kosaka K., Iseki E., Dementia with Lewy bodies Current Opinion in Neurology 1996 9 4 271 275
9. Trojanowski J. Q., Lee V. M., Parkinsons disease and related -synucleinopathies are brain amyloidoses Annals of the New York Academy of Sciences 2003 991 107 110
10. Dev K. K., Hofele K., Barbieri S., Buchman V. L., van der Putten H., Part II: -synuclein and its molecular pathophysiological role in neurodegenerative disease Neuropharmacology 2003 45 1 14 44
11. Uversky V. N., Neuropathology, biochemistry, and biophysics of -synuclein aggregation Journal of Neurochemistry 2007 103 1 17 37
12. Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L., Goedert M., Filamentous -synuclein inclusions link multiple system atrophy with Parkinsons disease and dementia with Lewy bodies Neuroscience Letters 1998 251 3 205 208
13. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., Goedert M., -synuclein in filamentous inclusions of Lewy bodies from Parkinsons disease and dementia with Lewy bodies Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6469 6473
14. Polymeropoulos M. H., Lavedan C., Leroy E., Mutation in the -synuclein gene identified in families with Parkinsons disease Science 1997 276 5321 2045 2047
15. Kruger R., Kuhn W., Muller T., Ala30Pro mutation in the gene encoding -synuclein in Parkinsons disease Nature Genetics 1998 18 2 106 108
16. Zarranz J. J., Alegre J., Gmez-Esteban J. C., The new mutation, E46K, of -synuclein causes Parkinson and Lewy body dementia Annals of Neurology 2004 55 2 164 173
17. Conway K. A., Lee S. J., Rochet J. C., Accelerated oligomerization by Parkinsons disease linked -synuclein mutants Annals of the New York Academy of Sciences 2000 920 42 45
18. Li J., Uversky V. N., Fink A. L., Effect of familial Parkinsons disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human -synuclein Biochemistry 2001 40 38 11604 11613
19. Chartier-Harlin M. C., Kachergus J., Roumier C., -synuclein locus duplication as a cause of familial Parkinsons disease The Lancet 2004 364 9440 1167 1169
20. Singleton A. B., Farrer M., Johnson J., -synuclein locus triplication causes Parkinsons disease Science 2003 302 5646 841
21. Volles M. J., Lansbury P. T. Jr., Zeroing in on the pathogenic form of -synuclein and its mechanism of neurotoxicity in Parkinsons disease Biochemistry 2003 42 26 7871 7878
22. Lashuel H. A., Petre B. M., Wall J., -synuclein, especially the parkinsons disease-associated mutants, forms pore-like annular and tubular protofibrils Journal of Molecular Biology 2002 322 5 1089 1102
23. Volles M. J., Lansbury P. T. Jr., Vesicle permeabilization by protofibrillar -synuclein is sensitive to Parkinsons disease-linked mutations and occurs by a pore-like mechanism Biochemistry 2002 41 14 4595 4602
24. Ding T. T., Lee S. J., Rochet J. C., Lansbury P. T. Jr., Annular -synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes Biochemistry 2002 41 32 10209 10217
25. Anguiano M., Nowak R. J., Lansbury P. T. Jr., Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes Biochemistry 2002 41 38 11338 11343
26. Arispe N., Architecture of the Alzheimers A P ion channel pore Journal of Membrane Biology 2004 197 1 33 48
27. Demuro A., Mina E., Kayed R., Milton S. C., Parker I., Glabe C. G., Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers Journal of Biological Chemistry 2005 280 17 17294 17300
28. Green J. D., Kreplak L., Goldsbury C., Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide Journal of Molecular Biology 2004 342 3 877 887
29. Findeis M. A., Approaches to discovery and characterization of inhibitors of amyloid -peptide polymerization Biochimica et Biophysica Acta 2000 1502 1 76 84
30. Cashman N. R., Caughey B., Prion diseasesclose to effective therapy? Nature Reviews Drug Discovery 2004 3 10 874 884
31. Heiser V., Scherzinger E., Boeddrich A., Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntingtons disease therapy Proceedings of the National Academy of Sciences of the United States of America 2000 97 12 6739 6744
32. Pickhardt M., Gazova Z., von Bergen M., Anthraquinones inhibit tau aggregation and dissolve Alzheimers paired helical filaments in vitro and in cells Journal of Biological Chemistry 2005 280 5 3628 3635
33. Taniguchi S., Suzuki N., Masuda M., Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins Journal of Biological Chemistry 2005 280 9 7614 7623
34. Pietta P. G., Flavonoids as antioxidants Journal of Natural Products 2000 63 7 1035 1042
35. Porat Y., Abramowitz A., Gazit E., Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chemical Biology and Drug Design 2006 67 1 27 37
36. Zhu M., Rajamani S., Kaylor J., Han S., Zhou F., Fink A. L., The flavonoid baicalein inhibits fibrillation of -synuclein and disaggregates existing fibrils Journal of Biological Chemistry 2004 279 26 26846 26857
37. Li J., Zhu M., Rajamani S., Uversky V. N., Fink A. L., Rifampicin inhibits -synuclein fibrillation and disaggregates fibrils Chemical Biology 2004 11 11 1513 1521
38. Hong D.-P., Fink A. L., Uversky V. N., Structural characteristics of the -synuclein oligomers stabilized by the flavonoid baicalein Journal of Molecular Biology 2008 383 1 214 223
39. Middleton E. Jr., Kandaswami C., Theoharides T. C., The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer Pharmacological Reviews 2000 52 4 673 751
40. Larson R. A., The antioxidants of higher plants Phytochemistry 1988 27 4 969 978
41. Jovanovic S. V., Steenken S., Hara Y., Simic M. G., Reduction potentials of flavonoid and model phenoxyl radicals. Which ring in flavonoids is responsible for antioxidant activity? Journal of the Chemical Society, Perkin Transactions 1996 2 2497 2504
42. Buettner G. R., The pecking order of free radicals and antioxidants: lipid peroxidation, -tocopherol, and ascorbate Archives of Biochemistry and Biophysics 1993 300 2 535 543
43. Robak J., Gryglewski R. J., Flavonoids are scavengers of superoxide anions Biochemical Pharmacology 1988 37 5 837 841
44. Husain S. R., Cillard J., Cillard P., Hydroxyl radical scavenging activity of flavonoids Phytochemistry 1987 26 9 2489 2491
45. Torel J., Cillard J., Cillard P., Antioxidant activity of flavonoids and reactivity with peroxy radical Phytochemistry 1986 25 2 383 385
46. Gutteridge J. M., Halliwell B., Free radicals and antioxidants in the year 2000. A historical look to the future Annals of the New York Academy of Sciences 2000 899 136 147
47. Amic D., Davidovic-Amic D., Beslo D., Trinajstic N., Structure-radical scavenging activity relationships of flavonoids Croatica Chemica Acta 2003 76 1 55 61
48. Nordberg J., Arner E. S., Reactive oxygen species, antioxidants, and the mammalian thioredoxin system Free Radical Biology and Medicine 2001 31 11 1287 1312
49. Patel M. N., Oxidative stress, mitochondrial dysfunction, and epilepsy Free Radical Research 2002 36 11 1139 1146
50. Butterfield D. A., Kanski J., Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins Mechanisms of Ageing and Development 2001 122 9 945 962
51. Giasson B. I., Duda J. E., Murray I. V., Oxidative damage linked to neurodegeneration by selective -synuclein nitration in synucleinopathy lesions Science 2000 290 5493 985 989
52. Giasson B. I., Ischiropoulos H., Lee V. M., Trojanowski J. Q., The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimers and Parkinsons diseases Free Radical Biology and Medicine 2002 32 12 1264 1275
53. Zhang Y., Dawson V. L., Dawson T. M., Oxidative stress and genetics in the pathogenesis of parkinsons disease Neurobiology of Disease 2000 7 4 240 250
54. Okawa M., Kinjo J., Nohara T., Ono M., DPPH (1,1-diphenyl-2- Picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants Biological and Pharmaceutical Bulletin 2001 24 10 1202 1205
55. Heijnen C. G., Haenen G. R., van Acker F. A., van der Vijgh W. J., Bast A., Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups Toxicology in Vitro 2001 15 1 3 6
56. Heijnen C. G., Haenen G. R., Oostveen R. M., Stalpers E. M., Bast A., Protection of flavonoids against lipid peroxidation: the structure activity relationship revisited Free Radical Research 2002 36 5 575 581
57. Arora A., Nair M. G., Strasburg G. M., Structure-activity relationships for antioxidant activities of a series of flavonoids in a liposomal system Free Radical Biology and Medicine 1998 24 9 1355 1363
58. Di Carlo G., Mascolo N., Izzo A. A., Capasso F., Flavonoids: old and new aspects of a class of natural therapeutic drugs Life Sciences 1999 65 4 337 353
59. Bors W., Heller W., Michel C., Saran M., Radical chemistry of flavonoid antioxidants Advances in Experimental Medicine and Biology 1990 264 165 170
60. Bors W., Heller W., Michel C., Saran M., Flavonoids as antioxidants: determination of radical-scavenging efficiencies Methods in Enzymology 1990 186 343 355
61. Nielsen L., Frokjaer S., Brange J., Uversky V. N., Fink A. L., Probing the mechanism of insulin fibril formation with insulin mutants Biochemistry 2001 40 28 8397 8409
62. Joseph J. A., Shukitt-Hale B., Denisova N. A., Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation Journal of Neuroscience 1999 19 18 8114 8121
63. Commenges D., Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gateau P., Dartigues J. F., Intake of flavonoids and risk of dementia European Journal of Epidemiology 2000 16 4 357 363
64. Levites Y., Weinreb O., Maor G., Youdim M. B., Mandel S., Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration Journal of Neurochemistry 2001 78 5 1073 1082
65. Griffioen G., Duhamel H., van Damme N., A yeast-based model of -synucleinopathy identifies compounds with therapeutic potential Biochimica et Biophysica Acta 2006 1762 3 312 318
66. Conway K. A., Harper J. D., Lansbury P. T., Accelerated in vitro fibril formation by a mutant -synuclein linked to early-onset Parkinson disease Nature Medicine 1998 4 11 1318 1320
67. Sang S., Lambert J. D., Yang C. S., Bioavailability and stability issues in understanding the cancer preventive effects of tea polyphenols Journal of the Science of Food and Agriculture 2006 86 14 2256 2265
68. Meng X., Munishkina L. A., Fink A. L., Uversky V. N., Molecular mechanisms underlying the flavonoid-induced inhibition of -synuclein fibrillation Biochemistry 2009 48 34 8206 8224
69. Lebeau A., Esclaire F., Rostene W., Pelaprat D., Baicalein protects cortical neurons from -amyloid (2535) induced toxicity Neuroreport 2001 12 10 2199 2202
70. Perry E. K., Pickering A. T., Wang W. W., Houghton P. J., Perry N. S., Medicinal plants and Alzheimers disease: from ethnobotany to phytotherapy Journal of Pharmacy and Pharmacology 1999 51 5 527 534
71. Watanabe C. M., Wolffram S., Ader P., The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba Proceedings of the National Academy of Sciences of the United States of America 2001 98 12 6577 6580
72. Hertog M. G., Feskens E. J., Hollman P. C., Katan M. B., Kromhout D., Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study The Lancet 1993 342 8878 1007 1011
73. Hertog M. G., Kromhout D., Aravanis C., Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study Archives of Internal Medicine 1995 155 4 381 386
74. Rimm E. B., Katan M. B., Ascherio A., Stampfer M. J., Willett W. C., Relation between intake of flavonoids and risk for coronary heart disease in male health professionals Annals of Internal Medicine 1996 125 5 384 389
75. Williams R. J., Spencer J. P., Rice-Evans C., Flavonoids: antioxidants or signalling molecules? Free Radical Biology and Medicine 2004 36 7 838 849
76. Frei B., Higdon J. V., Antioxidant activity of tea polyphenols in vivo: evidence from animal studies Journal of Nutrition 2003 133 10 3275S 3284S
77. Zhao B., Natural antioxidants for neurodegenerative diseases Molecular Neurobiology 2005 31 13 283 293
78. Spencer J. P., Rice-Evans C., Williams R. J., Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability Journal of Biological Chemistry 2003 278 37 34783 34793
79. Masuda M., Suzuki N., Taniguchi S., Small molecule inhibitors of -synuclein filament assembly Biochemistry 2006 45 19 6085 6094